Natraj Proteins Ltd (530119)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Natraj Proteins' revenue was ₹31.4 Cr (+18.3% year on year, +66.5% on the previous quarter), and net profit ₹2.1 Cr (against a loss a year earlier); the operating margin was 8.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹31.4 | +18.3% | +66.5% |
| Operating profit | ₹2.8 | from loss | +63.5% |
| Net profit | ₹2.1 | from loss | +89.7% |
| EPS (₹) | 5.62 | from loss | +89.9% |
| Operating margin | 8.9% | — | — |
📢 Recent Corporate Announcements
Natraj Proteins Ltd has announced the re-appointment of Shri Sharad Kumar Jain as Whole Time Director for a further period of 3 years, effective from October 1, 2026. The decision was approved by the Board on August 13, 2026, and remains subject to shareholder approval at the upcoming Annual General Meeting. Mr. Jain brings over 38 years of experience in the Soya industry, providing leadership continuity for the company which has a TTM revenue of ₹106 Cr. This move follows a recovery in financial performance, with the company reporting a PAT of ₹1.0 Cr in FY26 compared to a loss in FY25.
- Re-appointment of Shri Sharad Kumar Jain as Whole Time Director for a 3-year term starting October 1, 2026.
- The appointee possesses over 38 years of specialized experience in the Soya industry.
- The Board meeting approving the appointment concluded on August 13, 2026, after a 90-minute session.
- The company maintains a small-cap profile with a market capitalization of ₹15 Cr and TTM revenue of ₹106 Cr.
- Appointment is subject to final approval by members at the ensuing Annual General Meeting.
Natraj Proteins Ltd has appointed M/s Yogesh Chourasia and Associates as the Cost Auditor for the financial year ending March 31, 2027. The appointment was approved by the Board of Directors on August 13, 2026, following a recommendation from the Audit Committee. This is a routine regulatory compliance filing for the edible oil manufacturer, which reported a TTM revenue of Rs 106 Cr and a market capitalization of Rs 15 Cr. The appointment is effective immediately as of the board meeting date.
- Appointment of M/s Yogesh Chourasia and Associates (Firm Registration No. 000271) as Cost Auditor.
- Appointment is effective from August 13, 2026, for the financial year ending March 31, 2027.
- The company reported a net profit of Rs 2.1053 Cr for the quarter ended June 2026.
- Natraj Proteins operates with a TTM revenue of Rs 106 Cr and a debt-to-equity ratio of 1.06.
Natraj Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹2.11 cr compared to a loss of ₹1.21 cr in the same quarter last year. While revenue from operations declined 24% YoY to ₹20.18 cr, the company achieved profitability through aggressive cost management, with total expenses falling from ₹27.83 cr to ₹18.14 cr. The quarterly EPS of ₹5.62 is notably high relative to the current share price of ₹39.3. This performance marks a strong start to the fiscal year following a volatile FY26.
- Net Profit of ₹2.11 cr for Q1 FY27 vs a loss of ₹1.21 cr in Q1 FY26
- Revenue from operations decreased 24% YoY to ₹20.18 cr from ₹26.56 cr
- Total expenses reduced by 34.8% YoY to ₹18.14 cr from ₹27.83 cr
- Quarterly EPS reached ₹5.62, significantly higher than the TTM EPS of ₹3.04
- Finance costs remained relatively stable at ₹0.38 cr compared to ₹0.29 cr YoY
Natraj Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹2.10 Cr compared to a net loss of ₹1.21 Cr in the same quarter last year. This profitability surge occurred despite a 24% YoY decline in revenue to ₹20.18 Cr, primarily driven by a sharp reduction in raw material costs which fell from ₹22.26 Cr to ₹8.36 Cr. The quarterly EPS of ₹5.62 is notably higher than the entire TTM EPS of ₹3.04, representing a substantial improvement for this micro-cap company.
- Net Profit turned positive at ₹2.10 Cr for Q1 FY27 against a loss of ₹1.21 Cr in Q1 FY26.
- Revenue from operations decreased by 24% YoY to ₹20.18 Cr from ₹26.56 Cr.
- Cost of materials consumed dropped significantly to ₹8.36 Cr from ₹22.26 Cr in the previous year's quarter.
- Quarterly EPS stands at ₹5.62, which is approximately 14% of the current share price (₹39.3).
- Board recommended re-appointment of Sharad Kumar Jain as Whole Time Director for 3 years effective October 1, 2026.
Natraj Proteins Ltd has scheduled a board meeting for August 13, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The company, operating in the edible oil sector, reported a TTM revenue of ₹101 Cr and a thin PAT of ₹1 Cr. Given its micro-cap status (₹14 Cr market cap) and a debt-to-equity ratio of 1.06, these results are critical for assessing the company's recovery from a loss-making FY25. The trading window for insiders is currently closed and will reopen 48 hours after the results are disseminated.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results.
- Trading window remains closed until 48 hours post-result declaration.
- Company reported a TTM revenue of ₹101 Cr against a small market cap of ₹14 Cr.
- Operating profit margin stands at a lean 3.6% based on TTM data.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
